Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 55.85% is 230% above its 5-year average of -43.05%, near the high end of its 5-year range (-53.09%–55.85%).
226.21% above its 12-month average of -44.25%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -1.88%.
RETURN ON ASSETS (ROA)
55.85%
RETURN ON ASSETS (ROA) AVG TTM
-44.25%
RETURN ON ASSETS (ROA) AVG 3Y
-43.62%
RETURN ON ASSETS (ROA) AVG 5Y
-43.05%
RETURN ON ASSETS (ROA) AVG 10Y
-55.67%
RETURN ON ASSETS (ROA) AVG 15Y
-39.23%
RETURN ON ASSETS (ROA) AVG 20Y
-36.11%
CURRENT VS TTM AVG
+226.21%
CURRENT VS 3Y AVG
+228.03%
CURRENT VS 5Y AVG
+229.74%
CURRENT VS 10Y AVG
+200.32%
CURRENT VS 15Y AVG
+242.36%
CURRENT VS 20Y AVG
+254.66%
SECTOR MEDIAN · HEALTHCARE
-26.34%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
+311.99%
vs the sector median at left
Arbutus Biopharma Corp
Market Cap
$922.50M
Return on Assets (ROA)
55.85%
TTM Avg
-44.25%
3Y Avg
-43.62%
5Y Avg
-43.05%
Market Cap
$921.45M
Return on Assets (ROA)
4.06%
TTM Avg
3.72%
3Y Avg
3.23%
5Y Avg
2.82%
Market Cap
$915.95M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
Market Cap
$903.13M
Return on Assets (ROA)
-22.62%
TTM Avg
-55.95%
3Y Avg
-57.94%
5Y Avg
-46.38%
Market Cap
$942.78M
Return on Assets (ROA)
-50.49%
TTM Avg
-30.32%
3Y Avg
-31.10%
5Y Avg
-27.11%
Market Cap
$943.26M
Return on Assets (ROA)
-39.67%
TTM Avg
-22.62%
3Y Avg
-34.56%
5Y Avg
-34.56%
Market Cap
$867.60M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$985.79M
Return on Assets (ROA)
-56.27%
TTM Avg
-37.98%
3Y Avg
-21.94%
5Y Avg
-21.15%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $922.50M | 55.85% | -44.25% | -43.62% | -43.05% |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 4.06% | 3.72% | 3.23% | 2.82% |
| Bioventus Inc. (BVS)vs › | $915.95M | 8.09% | -0.64% | -8.03% | -4.54% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | -22.62% | -55.95% | -57.94% | -46.38% |
| Kura Oncology, Inc. (KURA)vs › | $942.78M | -50.49% | -30.32% | -31.10% | -27.11% |
| CeriBell, Inc. (CBLL)vs › | $943.26M | -39.67% | -22.62% | -34.56% | -34.56% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -23.15% | -12.59% | -25.36% | -32.38% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | -56.27% | -37.98% | -21.94% | -21.15% |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | -32.46% | -61.56% | -55.11% | -72.90% |
ROA
55.9%
ROE
59.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -35.41% |
| 2024-12-31 | -53.09% |
| 2023-12-31 | -50.45% |
| 2022-12-31 | -35.54% |
| 2021-12-31 | -37.29% |
| 2020-12-31 | -46.50% |
| 2019-12-31 | -145.66% |
| 2018-12-31 | -25.05% |
| 2017-12-31 | -35.58% |
| 2016-12-31 | -139.22% |
| 2015-12-31 | -8.58% |
| 2014-12-31 | -32.83% |
| 2013-12-31 | -19.61% |
| 2012-12-31 | 56.93% |
| 2011-12-31 | -71.02% |
| 2010-12-31 | -59.06% |
| 2009-12-31 | -22.23% |
| 2008-12-31 | -27.67% |
| 2007-12-31 | -10.40% |
| 2006-12-31 | 299.61% |
| 2005-12-31 | -43.58% |
| 2004-12-31 | -68.25% |
| 2003-12-31 | -67.17% |
| 2002-12-31 | -50.35% |
| 2001-12-31 | -20.73% |
| 2000-12-31 | -28.30% |
| 1999-12-31 | -28.38% |
| 1998-12-31 | -55.29% |
